42
Participants
Start Date
July 31, 2007
Primary Completion Date
February 28, 2011
Study Completion Date
February 28, 2011
Patupilone
RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
RAD001
RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
The Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
National Cancer Institute (NCI)
NIH
University of Medicine and Dentistry of New Jersey
OTHER